VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > COVID-19 and Heart Failure

<< Previous

Bullboard Posts

Next >>

Comment by wanttoretireearlyon Oct 04, 2020 9:26pm

226 Views

Post# 31665188

RE:RE:RE:RE:COVID-19 and Heart Failure

Yes indeed. More news will be flowing in slowly.
I said it before and I will say it again, soon or later someone like Toshiba, Siemens, GE, Metronix might buy out VPT since Philips controls most of the advance cardiac analitics market now.
GA ... "Philips owns advance cardiac analitics space, beside us"... "now we are talking to others"

others = Toshiba, Siemens, GE, Metronix

COVID-19 and latest data on heart coriliation might only speed things up in our favour.

<< Previous

Bullboard Posts

Next >>

How to trade on the stock market: A beginner’s guide